Sökning: onr:"swepub:oai:DiVA.org:uu-162584" >
Prognostic Relevanc...
-
Ekeblad, SaraUppsala universitet,Institutionen för medicinska vetenskaper,Endokrin tumörbiologi
(författare)
Prognostic Relevance of Survivin in Pancreatic Endocrine Tumors
- Artikel/kapitelEngelska2012
Förlag, utgivningsår, omfång ...
-
2011-11-17
-
Springer Science and Business Media LLC,2012
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-162584
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-162584URI
-
https://doi.org/10.1007/s00268-011-1345-7DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BACKGROUND: Better prognostic markers are needed for pancreatic endocrine tumors. Survivin is an apoptosis inhibitor that is suggested to have a negative prognostic impact in several tumor types. Contradictory data exist, especially regarding the significance of a nuclear versus cytoplasmic location of survivin. The prognostic relevance of nuclear and cytoplasmic survivin expression in pancreatic endocrine tumors-controlled for the tumor Ki-67 index, World Health Organization classification, and TNM stage-was investigated. METHODS: A total of 111 patients treated at a tertiary referral center were retrospectively evaluated. Clinical data were gathered from medical records. Immunohistochemistry for survivin and Ki-67 was performed on paraffin-embedded tissue. Univariate and multivariate Cox analyses were performed. RESULTS: Patients with tumors that had <5% survivin-positive nuclei had a mean survival of 225 months [95% confidence interval (CI) 168-281]. The corresponding figure for patients with 5 to 50% survivin-positive tumor cell nuclei was 101 months [95% CI 61-140; hazard ratio (HR) 2.4; P < 0.01) and with >50% survivin-positive nuclei 47 months (95% CI 24-71; HR 4.9; P < 0.001). Nuclear survivin expression in >50% of the tumor cells was an independent marker of a poor prognosis (HR 5.7; P < 0.01). Cytoplasmic survivin was not a significant prognostic factor in the multivariate analysis (HR 0.94; P = 0.90). CONCLUSIONS: High expression of nuclear survivin is a significant marker of a poor prognosis in patients with a pancreatic endocrine tumor.
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Halin Lejonklou, MargaretaUppsala universitet,Institutionen för medicinska vetenskaper,Endokrin tumörbiologi(Swepub:uu)marghali
(författare)
-
Stålberg, PeterUppsala universitet,Endokrinkirurgi(Swepub:uu)petestah
(författare)
-
Skogseid, BrittUppsala universitet,Institutionen för medicinska vetenskaper,Endokrin tumörbiologi(Swepub:uu)brittsko
(författare)
-
Uppsala universitetInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:World Journal of Surgery: Springer Science and Business Media LLC36:6, s. 1411-14180364-23131432-2323
Internetlänk
Hitta via bibliotek
Till lärosätets databas